- Source type
- Article
- Access type
- Publisher
- Publisher
- Times of India
- Date
- 2026-06-28
- Added
- 2026-07-08
Trust profile
VV Source Trust Matrix v1.0
VV Source Trust Matrix v1.0 asks whether this source is trustworthy for the claim lane being used, not whether every possible claim from it is equally strong.
60
General published source
- Publisher type
- General media
- Bias profile
- Elevated
This source is strongest for consumer context and regulatory status and weaker for safety and trial discovery.
VV Source Fit Score 1.0
Fit by use case
Fit scores are role-specific. A source can be excellent for one claim lane and weak for another.
- Regulatory status
- 54/100
- Weak Support
- Clinical outcomes
- 54/100
- Weak Support
- Mechanism
- 54/100
- Weak Support
- Safety
- 54/100
- Weak Support
- Consumer context
- 67/100
- Context Source
- Trial discovery
- 54/100
- Weak Support
Best used for
- Context
- Public narrative
Weak for
- Clinical claims
- Safety conclusions
- Regulatory status
Used in Viral Vitalism
Aging Faster May Be Part of the Early-Onset Cancer Puzzle
Roles: Background
Related studies
No structured study record is currently attached to this source.
Related sources
ClinicalTrials.gov: ReMIND trial
Canonicalized from June 30, 2026 rapid-brief batch.
- Trust score
- 84
- Publisher
- ClinicalTrials.gov
- Access
- Official
- Usage
- 1 connection
Nature Medicine: biological aging and generational shifts in early-onset cancer
Canonical source record for the republished rapid brief accelerated-biological-aging-early-onset-cancer-risk.
- Trust score
- 91
- Publisher
- Nature Medicine
- Access
- Publisher
- Usage
- 1 connection
CIRM: clinical and preclinical development awards
Canonicalized from June 30, 2026 rapid-brief batch.
- Trust score
- 91
- Publisher
- CIRM
- Access
- Official
- Usage
- 1 connection
ClinicalTrials.gov: trial registry search for FourLight-3 context
Canonical source record for the republished rapid brief jamie-lynne-tarailo-breast-cancer-trial-close-to-home.
- Trust score
- 91
- Publisher
- ClinicalTrials.gov
- Access
- Official
- Usage
- 2 connections
FDA: approves sacituzumab govitecan-hziy for first-line TNBC indications
Canonical source record for the republished rapid brief fda-trodelvy-first-line-triple-negative-breast-cancer.
- Trust score
- 94
- Publisher
- FDA
- Access
- Official
- Usage
- 1 connection
FDA: bulk drug substances for compounding that may present significant safety risks
Canonical source record for the republished rapid brief fda-peptide-review-bpc-157-tb-500-mots-c-semax-epitalon.
- Trust score
- 94
- Publisher
- FDA
- Access
- Official
- Usage
- 1 connection